文献速递消化道肿瘤放疗

局部晚期胰腺癌大分割质子SIB治疗:治疗顺序与剂量反应对结局的影响

Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simultaneous integrated boost technique.
PubMed 文献 · Radiother Oncol · 2025-11-19

该研究回顾225例接受大分割同步整合推量(SIB)质子束治疗(PBT)的局部晚期胰腺癌(LAPC)患者,按治疗顺序分三组。结果显示诱导化疗后疾病稳定再行PBT组总生存优于进展后PBT组及PBT后维持化疗组,50 Gy(RBE)组生存更优,提示潜在剂量反应关系,晚期≥3级胃肠道不良事件为4%。

要点

  • 诱导化疗后疾病稳定再行SIB-PBT的患者总生存最优
  • 50 Gy(RBE)组从首次治疗起总生存显著优于较低剂量组
  • 急性不良事件多为1-2级,晚期≥3级胃肠道事件为4%

核心结论

  • 大分割SIB-PBT可能是LAPC安全有效的局部治疗,诱导化疗后稳定期行PBT结局较好,并提示潜在剂量反应关系,仍需前瞻性研究验证。

研究设计与样本

  • 回顾性研究,纳入225例连续接受SIB-PBT的LAPC患者,PTV1 45-50 Gy(RBE)、PTV2 30 Gy(RBE),均10次分割。
  • 按治疗顺序分三组:诱导化疗后稳定期行PBT(Group I,48.9%)、诱导化疗后进展行PBT(Group II,15.6%)、PBT后维持化疗(Group III,35.6%)。

主要发现

  • 自首次治疗和自PBT起中位总生存分别为24.2个月(95%CI 21.7-26.7)和19.5个月(95%CI 17.4-21.7)。
  • Group I自首次治疗和自PBT起总生存均显著长于Group II和Group III(31.1 vs 21.1和19.1个月;23.7 vs 9.9和19.1个月;每项p<0.05)。
  • 接受50 Gy(RBE)者自首次治疗总生存显著更优(25.6 vs 19.3个月;p=0.001),自PBT总生存有更优趋势(20.3 vs 18.3个月;p=0.062)。
  • 急性不良事件多为1-2级,晚期≥3级胃肠道事件为4%。

关键数值与推荐

  • SIB-PBT剂量:PTV1 45-50 Gy(RBE),PTV2 30 Gy(RBE),10次分割。
  • 分组比例:Group I 48.9%、Group II 15.6%、Group III 35.6%。
  • 50 Gy(RBE)与较低剂量比较:自首次治疗总生存25.6 vs 19.3个月(p=0.001)。

临床怎么用

  • 对LAPC可在诱导化疗后疾病稳定时考虑大分割SIB-PBT,并关注剂量选择与治疗顺序对生存的影响。

局限性

  • 为回顾性研究,作者指出需进一步前瞻性研究验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of hypofractionated simultaneous integrated boost (SIB) - proton beam therapy (PBT) with systemic treatment and also to explore survival-related prognostic factors, including treatment sequencing and dose-response. METHODS: We reviewed 225 consecutive patients with LAPC treated with SIB-PBT (45-50 Gy[RBE] for PTV1 and 30 Gy[RBE] for PTV2 in 10 fractions). The patients were grouped by treatment sequence as follows: PBT after stable disease post-induction chemotherapy (Group I, 48.9 %), PBT after progression post-induction chemotherapy (Group II, 15.6 %), and PBT followed by maintenance chemotherapy (Group III, 35.6 %). RESULTS: Median overall survival (OS) from first treatment and PBT was 24.2 (95 % CI, 21.7-26.7) and 19.5 (95 % CI, 17.4-21.7) months, respectively. Group I had significantly longer OS than Groups II and III from first treatment (31.1 vs. 21.1 and 19.1 months) and PBT (23.7 vs. 9.9 and 19.1 months) (p < 0.05 each). Patients receiving 50 Gy(RBE) had significantly better OS from first treatment (25.6 vs. 19.3 months; p = 0.001) and a trend towards better OS from PBT (20.3 vs. 18.3 months; p = 0.062). Most acute adverse events were grade 1-2, with late grade ≥ 3 gastrointestinal events in 4 %. CONCLUSION: This largest to-date study on PBT for LAPC suggests that hypofractionated SIB-PBT could be a safe and effective local treatment for LAPC. Favorable outcomes were observed with PBT after stable disease following induction chemotherapy, and a potential dose-response relationship was suggested. However, further prospective studies are required to validate our findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kim TH, Chun JW, Woo SM, et al. Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simultaneous integrated boost technique. Radiother Oncol. 2025. PMID: 41271172. doi:10.1016/j.radonc.2025.111295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。